Gemfibrozil Tablet
Product Images NDC 50090-7809

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 50090-7809). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Additional Adverse Reactions (Additional Adv Drug Reactions)

Additional Adverse Reactions (Additional Adv Drug Reactions)
This text provides information on potential adverse effects and side effects of a medication. It lists various symptoms and conditions related to the central nervous system, gastrointestinal system, genitourinary system, musculoskeletal system, clinical laboratory findings, hematopoietic system, immunologic system, and integumentary system. Some examples of the listed effects include weight loss, cardiac issues, gastrointestinal problems, CNS issues like dizziness and confusion, musculoskeletal pain, laboratory abnormalities, immunologic reactions, and skin conditions. The medication appears to have a wide range of potential side effects and interactions that should be considered.*
FDA Label Image

Adverse Reactions (Adv Reactions)

Adverse Reactions (Adv Reactions)
FDA Label Image

Struct (Structure Gemfibrozil)

Struct (Structure Gemfibrozil)
FDA Label Image

Table1 (Table 1)

Table1 (Table 1)
Table showing the reduction in Coronary Heart Disease (CHD) rates per 1000 patients based on baseline lipid levels in the Helsinki Heart Study. The data includes the number of events over a period of 0-5 years for all patients and specific lipid categories such as LDL-C, HDL-C, and TG. Comparisons between placebo and Gemfibrozil groups are provided for different lipid levels in mg/dL. The table lists the occurrence of fatal and nonfatal events like myocardial infarctions and sudden cardiac deaths.*
FDA Label Image

Table2 (Table 2)

Table2 (Table 2)
This text provides a table showing the number of cardiac events and all-cause mortality per 1000 patients that occurred during a 3.5-year open-label follow-up to the Helsinki Heart Study. The groups are categorized based on the original randomization (P = placebo, G = Gemfibrozil) and by the drug taken during the follow-up period (N = Attend clinic but took no drug, G = Gemfibrozil, Drop = No attendance at clinic during open-label). The data includes patient numbers and event rates for cardiac events and all-cause mortality in each group.*
FDA Label Image

Table3 (Table 3)

Table3 (Table 3)
This text provides a detailed comparison of cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality in the Helsinki Heart Study over a span of 8.5 years, specifically analyzing the impact of gemfibrozil versus a placebo. The analysis includes hazard ratios and confidence intervals for various events such as cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality. The study uses an intention-to-treat analysis and focuses on originally randomized patients while disregarding open-label treatment switches and exposure to study conditions. The data presented relates to fatal and non-fatal myocardial infarctions along with sudden cardiac deaths over the 8.5-year duration.*
FDA Label Image

Label Image (Lbl500907809)

Label Image (Lbl500907809)
This is a product description for Gemfibrozil USP 600mg tablets with a product number of 53695-0. Each bottle contains 90 tablets and is available for purchase. The tablets are stored in a secure container.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.